Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets

被引：0
作者：
Cho, William C. S. [1 ]
Roukos, Dimitrios H. [2 ]
机构：
[1] Queen Elizabeth Hosp, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China
[2] GenNetMed Ioannina Univ, Ctr Biosyst & Genom Network Med CBS, Ioannina, Greece
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2013年 / 13卷 / 01期
关键词：
breast cancer; drugs; genome; HER2-positive; trastuzumab; trastuzumab emtansine; NEXT-GENERATION; PHASE-II; ARCHITECTURE; LAPATINIB; PLUS;
D O I：
10.1586/ERA.12.152
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：5 / 8
页数：4
相关论文
共 50 条
  • [31] Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model
    Negar Pourjamal
    Narjes Yazdi
    Aleksi Halme
    Vadim Le Joncour
    Pirjo Laakkonen
    Pipsa Saharinen
    Heikki Joensuu
    Mark Barok
    [J]. Clinical & Experimental Metastasis, 2024, 41 : 91 - 102
  • [32] Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
    Mueller, Volkmar
    Clemens, Michael
    Jassem, Jacek
    Al-Sakaff, Nedal
    Auclair, Petra
    Nuesch, Eveline
    Holloway, Debbie
    Shing, Mona
    Bang, Yung-Jue
    [J]. BMC CANCER, 2018, 18
  • [33] Trastuzumab emtansine: determining its role in management of HER2+ breast cancer
    Doroshow, Deborah B.
    LoRusso, Patricia M.
    [J]. FUTURE ONCOLOGY, 2018, 14 (07) : 589 - 602
  • [34] Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model
    Pourjamal, Negar
    Yazdi, Narjes
    Halme, Aleksi
    Le Joncour, Vadim
    Laakkonen, Pirjo
    Saharinen, Pipsa
    Joensuu, Heikki
    Barok, Mark
    [J]. CLINICAL & EXPERIMENTAL METASTASIS, 2024, 41 (02) : 91 - 102
  • [35] FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
    Amiri-Kordestani, Laleh
    Blumenthal, Gideon M.
    Xu, Qiang Casey
    Zhang, Lijun
    Tang, Shenghui W.
    Ha, Linan
    Weinberg, Wendy C.
    Chi, Bo
    Candau-Chacon, Reyes
    Hughes, Patricia
    Russell, Anne M.
    Miksinski, Sarah Pope
    Chen, Xiao Hong
    McGuinn, W. David
    Palmby, Todd
    Schrieber, Sarah J.
    Liu, Qi
    Wang, Jian
    Song, Pengfei
    Mehrotra, Nitin
    Skarupa, Lisa
    Clouse, Kathleen
    Al-Hakim, Ali
    Sridhara, Rajeshwari
    Ibrahim, Amna
    Justice, Robert
    Pazdur, Richard
    Cortazar, Patricia
    [J]. CLINICAL CANCER RESEARCH, 2014, 20 (17) : 4436 - 4441
  • [36] Role of subcutaneous formulation of trastuzumab in the treatment of patients with HER2-positive breast cancer
    Melichar, Bohuslav
    Studentova, Hana
    Kalabova, Hana
    Vitaskova, Denisa
    [J]. IMMUNOTHERAPY, 2014, 6 (07) : 811 - 819
  • [37] Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer
    Yamamoto, Harukaze
    Ando, Masashi
    Aogi, Kenjiro
    Iwata, Hiroji
    Tamura, Kenji
    Yonemori, Kan
    Shimizu, Chikako
    Hara, Fumikata
    Takabatake, Daisuke
    Hattori, Masaya
    Asakawa, Takashi
    Fujiwara, Yasuhiro
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (01) : 12 - 18
  • [38] Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer
    Van den Mooter, Tom
    Teuwen, Laure-Anne
    Rutten, Annemie
    Dirix, Luc
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (05) : 749 - 760
  • [39] Duration of trastuzumab for HER2-positive breast cancer
    Montemurro, Filippo
    Aglietta, Massimo
    [J]. LANCET ONCOLOGY, 2013, 14 (08) : 678 - 679
  • [40] Her2-positive breast cancer: Herceptin and beyond
    Dean-Colomb, Windy
    Esteva, Francisco J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2008, 44 (18) : 2806 - 2812
12345